BETAPLUS PHARMA has been active since 2002 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €22.3m and a net result of €1.3m. Equity is growing by about 7.6% per year across the filed financial years. Its solvency ranks better than 92% of 91 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Auditor: NV Callens Vandelanotte2025 accounts filed 3 days late
Why 96raises riskLiquidity: current ratio 24.55, cash €14,655lowers riskFounded in 2002Size: turnover €5.4m, 11.3 FTE, total assets €24.9mProfit of €1.3m (financial year 2025)Show the evidence
Checked score
Score 2025
Checked score
A figure from 0 to 100: the higher it is, the smaller the chance that the company goes bankrupt within twelve months. The band, from Critical to Excellent, follows from that chance; within the band, how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
96/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 70% of its sector peers (NACE 21, small)
How strong the balance sheet and results are: solvency, liquidity and profitability from the latest annual accounts, each out of 100. It does not directly set the Checked score's band; how the company does on these and on growth against its sector peers does count for its place within the band.
Strong
Solvency100=
equity 89.8% of total assets
Liquidity50=
short-term debt 3.9% · cash 0.1%
Profitability83-2
return on assets 5.1%
Bankruptcy probability, 12 months
Bankruptcy probability
The chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. 0.2% means about 2 in 1,000 comparable companies. The higher it is, the shorter the payment term to agree.
0.1%Very low
0%0.5%1.5%4%10%≥ 25%
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Sector median 0.4% (43 companies, NACE 21, small)
Last 24 months11-2024: 0.2%12-2024: 0.2%● unchanged vs 11-202401-2025: 0.2%● unchanged vs 12-202402-2025: 0.2%● unchanged vs 01-202503-2025: 0.2%● unchanged vs 02-202504-2025: 0.2%● unchanged vs 03-202505-2025: 0.2%● unchanged vs 04-202506-2025: 0.2%● unchanged vs 05-202507-2025: 0.3%▲ +0.1 percentage points vs 06-202508-2025: 0.1%▼ -0.2 percentage points vs 07-202509-2025: 0.1%● unchanged vs 08-202510-2025: 0.1%● unchanged vs 09-202511-2025: 0.1%● unchanged vs 10-202512-2025: 0.1%● unchanged vs 11-202501-2026: 0.1%● unchanged vs 12-202502-2026: 0.1%● unchanged vs 01-2026lowest value03-2026: 0.1%● unchanged vs 02-202604-2026: 0.1%● unchanged vs 03-202605-2026: 0.1%● unchanged vs 04-202606-2026: 0.1%● unchanged vs 05-202607-2026: 0.1%● unchanged vs 06-202608-2026: 0.3%▲ +0.2 percentage points vs 07-2026highest value09-2026: 0.1%▼ -0.2 percentage points vs 08-202610-2026: 0.1%● unchanged vs 09-2026
Credit of up to €500,000 on 30-day terms is acceptable
Liquidity ample (current ratio 24.55, compared with 22.08 in 2024, above the usual 1.5; short-term debt: 3.9% and cash: 0.1% of total assets), and 10.2% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
75-100
Excellent
under 0.55%
60-74
Healthy
0.55% to 1.5%
45-59
Fair
1.5% to 4.2%
25-44
Weak
4.2% to 15.0%
0-24
Critical
over 15.0%
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small): better than 88% on solvency, 63% on liquidity, 81% on profitability and 46% on growth.
The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-08-2026, 3 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 7 days after the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 August (4 of the last 5 filed years within 31 days of that day).
2025 annual accounts filed late (3 days)Filed on 3 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00373364.
Turnover
Turnover
What the company sold in the financial year. Rising revenue points to growth; compare with last year and with the sector.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€24.9m2025Equity€22.3m2025Debt€1.0m2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€23.1m2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
EBIT margin23.2%2025Return on assets (ROA)5.1%2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency89.8%2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio24.552025
Average staff in full-time equivalents (FTE).
Staff (FTE)11.32025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
Net result€1.9m-€1.4m▼ 24.5%€1.4mwithin the sector's middle half▼ 1.1%€1.6mabove the sector's middle half▲ 14.4%€1.2mwithin the sector's middle half▼ 22.6%€1.0mwithin the sector's middle half▼ 21.3%€1.6mwithin the sector's middle half▲ 69.5%€1.3mwithin the sector's middle half▼ 22.6%
Equity€12.8m-€14.2m▲ 11.0%€15.6mwithin the sector's middle half▲ 9.8%€17.2mwithin the sector's middle half▲ 10.2%€18.4mwithin the sector's middle half▲ 7.2%€19.4mwithin the sector's middle half▲ 5.3%€21.1mwithin the sector's middle half▲ 8.5%€22.3mabove the sector's middle half▲ 6.0%
Total assets€15.5m-€16.8m▲ 8.5%€18.4mwithin the sector's middle half▲ 9.6%€19.9mwithin the sector's middle half▲ 8.0%€20.8mwithin the sector's middle half▲ 4.8%€21.9mwithin the sector's middle half▲ 5.1%€23.7mwithin the sector's middle half▲ 8.1%€24.9mwithin the sector's middle half▲ 5.1%
Working capital€12.6m-€14.2m▲ 12.7%€15.8mabove the sector's middle half▲ 11.4%€17.6mabove the sector's middle half▲ 11.8%€19.0mabove the sector's middle half▲ 7.4%€20.2mabove the sector's middle half▲ 6.4%€21.8mabove the sector's middle half▲ 8.2%€23.1mabove the sector's middle half▲ 5.6%
Solvency82.8%-84.7%▲ 1.9pp84.9%above the sector's middle half▲ 0.2pp86.6%above the sector's middle half▲ 1.7pp88.6%above the sector's middle half▲ 2.0pp88.7%above the sector's middle half▲ 0.1pp89.0%above the sector's middle half▲ 0.3pp89.8%above the sector's middle half▲ 0.8pp
Current ratio8.31-10.39▲ 2.0910.84above the sector's middle half▲ 0.4514.05above the sector's middle half▲ 3.2021.07above the sector's middle half▲ 7.0223.29above the sector's middle half▲ 2.2222.08above the sector's middle half▼ 1.2124.55above the sector's middle half▲ 2.47
Return on assets (ROA)12.0%-8.4%▼ 3.7pp7.6%within the sector's middle half▼ 0.8pp8.0%within the sector's middle half▲ 0.5pp5.9%within the sector's middle half▼ 2.1pp4.4%within the sector's middle half▼ 1.5pp6.9%within the sector's middle half▲ 2.5pp5.1%within the sector's middle half▼ 1.8pp
Staff (FTE)10.5-11.1▲ 5.7%11.6below the sector's middle half▲ 4.5%12.5within the sector's middle half▲ 7.8%11.5below the sector's middle half▼ 8.0%11.5within the sector's middle half=11.5within the sector's middle half=11.3within the sector's middle half▼ 1.7%
abovewithinbelowthe middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €24.9m
96.6%
Fixed assets€835,211 ▲ 4.9%
Current assets€24.0m ▲ 5.1%
Equity and liabilities €24.9m
89.8%
6%
Equity€22.3m ▲ 6.0%
Provisions€1.6m =
Debt€978,856 ▼ 5.4%
Debt's share of the balance-sheet total falls from 4.4% to 3.9%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€1.5m▼
2024 · €1.6m
Cash flow
€1.5m▼
2024 · €1.8m
Quick ratio
24.22▲
2024 · 21.83
Debt to equity
0.04▼
2024 · 0.05
ROE
5.7%▼
2024 · 7.8%
Interest coverage
14.64▼
2024 · 17.55
Debt ≤ 1 year
€978,856▼
2024 · €1.0m
Income taxes
€458,608▼
2024 · €507,679
Staff costs
€1.2m▼
2024 · €1.2m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observation
Peer companies
What happened to companies that once looked just like this one does now. It describes the group, not this company: the figures are counted, not predicted.
Of the 20,139 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95.0% are still going.
Small
20 years or older
solvency 30% or more
a profit of 5% of the balance sheet or more
0.2%went bankrupt
4.7%stopped otherwise
95.0%still going
For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,475 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
The companies in ten equal groups, from lowest to highest expected share.
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
3.0%
3.1%
10
5.6%
6.2%
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 20,139 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
Filed annual accountsAs filed with the NBB · 2025 against 2024 · 58 lines
Balance sheetCode20242025
Assets
Total assets20/58€23.7m€24.9m▲
Fixed assets21/28€0.8m€0.8m▲
Intangible fixed assets21€0€0.02m▲
Tangible fixed assets22/27€0.8m€0.8m▲
Land and buildings22€0.06m€0.1m▲
Plant, machinery and equipment23€0.6m€0.6m▲
Furniture and vehicles24€0.04m€0.02m▼
Leasing and similar rights25-€0.003m
Assets under construction and advance payments27€0.07m€0.05m▼
Financial fixed assets28€0.05m€0.04m▼
Current assets29/58€22.9m€24.0m▲
Stocks and contracts in progress3€0.3m€0.3m▲
Stocks30/36€0.3m€0.3m▲
Amounts receivable within one year40/41€22.5m€23.7m▲
Trade receivables40€0.6m€0.6m▼
Other amounts receivable41€21.9m€23.1m▲
Cash at bank and in hand54/58€0.002m€0.01m▲
Deferred charges and accrued income490/1€0.1m€0.02m▼
Equity and liabilities
Total equity and liabilities10/49€23.7m€24.9m▲
Equity10/15€21.1m€22.3m▲
Contributions10/11€2.4m€2.4m=
Capital10€2.0m€2.0m=
Issued capital100€2.0m€2.0m=
Contributions outside capital11€0.4m€0.4m=
Share premium1100/10€0.4m€0.4m=
Reserves13€0.2m€0.2m=
Non-distributable reserves130/1€0.2m€0.2m=
Legal reserve130€0.2m€0.2m=
Profit (loss) carried forward14€18.5m€19.7m▲
Provisions and deferred taxes16€1.6m€1.6m=
Provisions for liabilities and charges160/5€1.6m€1.6m=
Environmental obligations163€1.6m€1.6m=
Amounts payable17/49€1.0m€1.0m▼
Amounts payable within one year42/48€1.0m€1.0m▼
Trade debts44€0.7m€0.8m▲
Suppliers440/4€0.7m€0.8m▲
Taxes, remuneration and social security45€0.4m€0.2m▼
Taxes450/3€0.05m-
Remuneration and social security454/9€0.3m€0.2m▼
Income statementCode20242025
Turnover70€5.4m€5.4m▲
Goods, raw materials, services and sundry goods60/61€2.5m€2.7m▲
Remuneration, social security and pensions62€1.2m€1.2m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.2m€0.2m▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€445-€0.002m▼
Other operating charges640/8€0.02m€0.02m▼
Gross operating margin9900€2.8m€2.7m▼
Operating profit (loss)9901€1.4m€1.3m▼
Financial income75/76B€0.9m€0.6m▼
Recurring financial income75€0.9m€0.6m▼
Financial charges65/66B€0.09m€0.1m▲
Recurring financial charges65€0.09m€0.1m▲
Profit (loss) for the period before taxes9903€2.2m€1.7m▼
Income taxes67/77€0.5m€0.5m▼
Profit (loss) for the period9904€1.6m€1.3m▼
Profit (loss) for the period to be appropriated9905€1.6m€1.3m▼
Appropriation of the result
Profit (loss) to be appropriated9906€18.5m€19.7m▲
Profit (loss) brought forward from the previous period14P€16.8m€18.5m▲
Social balance sheet
Average headcount (FTE)908711.511.3▼
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Line
2018
2019
2020
2021
2022
2023
2024
2025
Change
Turnover70
€6.0m
€6.1m
€5.7m
€6.1m
€5.1m
€4.5m
€5.4m
€5.4m
▲ 0.3%
Goods, raw materials, services and sundry goods60/61
-
-
-
€2.2m
€2.2m
€2.3m
€2.5m
€2.7m
▲ 6.0%
Remuneration, social security and pensions62
-
-
-
€1.2m
€1.1m
€1.2m
€1.2m
€1.2m
▼ 1.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630
€0.3m
€0.3m
€0.3m
€0.3m
€0.2m
€0.2m
€0.2m
€0.2m
▲ 6.0%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4
-
-
-
-€221
-€0.001m
€0.001m
€445
-€0.002m
-
Provisions for liabilities and charges: additions (uses and reversals)635/8
-
-
-
€0.1m
€0.1m
€0.1m
-
-
-
Other operating charges640/8
-
-
-
€0.01m
€0.01m
€0.02m
€0.02m
€0.02m
▼ 2.1%
Gross operating margin9900
-
€3.3m
€3.3m
€3.9m
€3.0m
€2.2m
€2.8m
€2.7m
▼ 4.8%
Operating profit (loss)9901
€2.5m
€2.0m
€1.8m
€2.2m
€1.5m
€0.6m
€1.4m
€1.3m
▼ 9.3%
Financial income75/76B
-
-
-
€0.05m
€0.2m
€0.7m
€0.9m
€0.6m
▼ 32.9%
Recurring financial income75
€0.08m
€0.07m
€0.06m
€0.05m
€0.2m
€0.7m
€0.9m
€0.6m
▼ 32.9%
Financial charges65/66B
-
-
-
€0.003m
€0.009m
€0.03m
€0.09m
€0.1m
▲ 11.1%
Recurring financial charges65
€0.02m
€0.02m
€0.005m
€0.003m
€0.009m
€0.03m
€0.09m
€0.1m
▲ 11.1%
Debt charges650
€0.001m
-
-
-
-
-
-
-
-
Profit (loss) for the period before taxes9903
€2.7m
€2.0m
€1.9m
€2.3m
€1.6m
€1.4m
€2.2m
€1.7m
▼ 19.6%
Income taxes67/77
€0.8m
€0.6m
€0.5m
€0.7m
€0.4m
€0.4m
€0.5m
€0.5m
▼ 9.7%
Profit (loss) for the period9904
€1.9m
€1.4m
€1.4m
€1.6m
€1.2m
€1.0m
€1.6m
€1.3m
▼ 22.6%
Profit (loss) for the period to be appropriated9905
€1.9m
€1.4m
€1.4m
€1.6m
€1.2m
€1.0m
€1.6m
€1.3m
▼ 22.6%
Line
2018
2019
2020
2021
2022
2023
2024
2025
Change
Assets
Total assets20/58
€15.5m
€16.8m
€18.4m
€19.9m
€20.8m
€21.9m
€23.7m
€24.9m
▲ 5.1%
Fixed assets21/28
€1.2m
€1.1m
€1.0m
€0.9m
€0.9m
€0.8m
€0.8m
€0.8m
▲ 4.9%
Intangible fixed assets21
-
€0
-
-
€0.03m
€0
€0
€0.02m
-
Tangible fixed assets22/27
€1.1m
€1.1m
€1.0m
€0.8m
€0.9m
€0.8m
€0.8m
€0.8m
▲ 2.2%
Land and buildings22
-
-
-
€0.03m
€0.03m
€0.04m
€0.06m
€0.1m
▲ 59.8%
Plant, machinery and equipment23
-
-
-
€0.5m
€0.6m
€0.7m
€0.6m
€0.6m
▲ 3.3%
Furniture and vehicles24
-
-
-
€0.1m
€0.07m
€0.05m
€0.04m
€0.02m
▼ 46.0%
Leasing and similar rights25
-
-
-
-
-
-
-
€0.003m
-
Assets under construction and advance payments27
-
-
-
€0.1m
€0.1m
€0
€0.07m
€0.05m
▼ 30.3%
Financial fixed assets28
€0.05m
€0.03m
€0.04m
€0.04m
€0.03m
€0.03m
€0.05m
€0.04m
▼ 4.9%
Current assets29/58
€14.3m
€15.7m
€17.4m
€19.0m
€19.9m
€21.1m
€22.9m
€24.0m
▲ 5.1%
Stocks and contracts in progress3
€0.2m
€0.2m
€0.2m
€0.2m
€0.3m
€0.3m
€0.3m
€0.3m
▲ 24.4%
Stocks30/36
-
-
-
€0.2m
€0.3m
€0.3m
€0.3m
€0.3m
▲ 24.4%
Amounts receivable within one year40/41
€14.0m
€15.3m
€17.0m
€18.5m
€19.5m
€20.7m
€22.5m
€23.7m
▲ 5.3%
Trade receivables40
-
-
-
€0.5m
€0.4m
€0.3m
€0.6m
€0.6m
▼ 4.2%
Other amounts receivable41
-
-
-
€18.0m
€19.1m
€20.4m
€21.9m
€23.1m
▲ 5.6%
Cash at bank and in hand54/58
€0.03m
€0.03m
€0.06m
€0.2m
€0.04m
€0.01m
€0.002m
€0.01m
▲ 491%
Deferred charges and accrued income490/1
-
-
-
€0.05m
€0.04m
€0.04m
€0.1m
€0.02m
▼ 83.7%
Equity and liabilities
Total equity and liabilities10/49
€15.5m
€16.8m
€18.4m
€19.9m
€20.8m
€21.9m
€23.7m
€24.9m
▲ 5.1%
Equity10/15
€12.8m
€14.2m
€15.6m
€17.2m
€18.4m
€19.4m
€21.1m
€22.3m
▲ 6.0%
Contributions10/11
€2.0m
€2.0m
€2.0m
€2.4m
€2.4m
€2.4m
€2.4m
€2.4m
=
Capital10
-
-
-
€2.0m
€2.0m
€2.0m
€2.0m
€2.0m
=
Issued capital100
-
-
-
€2.0m
€2.0m
€2.0m
€2.0m
€2.0m
=
Contributions outside capital11
-
-
-
€0.4m
€0.4m
€0.4m
€0.4m
€0.4m
=
Share premium1100/10
-
-
-
€0.4m
€0.4m
€0.4m
€0.4m
€0.4m
=
Reserves13
€0.2m
€0.2m
€0.2m
€0.2m
€0.2m
€0.2m
€0.2m
€0.2m
=
Non-distributable reserves130/1
-
-
-
€0.2m
€0.2m
€0.2m
€0.2m
€0.2m
=
Legal reserve130
-
-
-
€0.2m
€0.2m
€0.2m
€0.2m
€0.2m
=
Profit (loss) carried forward14
€10.2m
€11.6m
€13.0m
€14.6m
€15.9m
€16.8m
€18.5m
€19.7m
▲ 6.9%
Provisions and deferred taxes16
€0.9m
€1.1m
€1.2m
€1.3m
€1.4m
€1.6m
€1.6m
€1.6m
=
Provisions for liabilities and charges160/5
-
-
-
€1.3m
€1.4m
€1.6m
€1.6m
€1.6m
=
Environmental obligations163
-
-
-
€1.3m
€1.4m
€1.6m
€1.6m
€1.6m
=
Amounts payable17/49
€1.7m
€1.5m
€1.6m
€1.4m
€0.9m
€0.9m
€1.0m
€1.0m
▼ 5.4%
Amounts payable within one year42/48
€1.7m
€1.5m
€1.6m
€1.4m
€0.9m
€0.9m
€1.0m
€1.0m
▼ 5.4%
Trade debts44
€0.8m
€1.1m
€1.2m
€0.9m
€0.5m
€0.6m
€0.7m
€0.8m
▲ 14.9%
Suppliers440/4
-
-
-
€0.9m
€0.5m
€0.6m
€0.7m
€0.8m
▲ 14.9%
Taxes, remuneration and social security45
-
-
-
€0.4m
€0.4m
€0.3m
€0.4m
€0.2m
▼ 44.3%
Taxes450/3
-
-
-
€0.3m
€0.2m
€0.1m
€0.05m
-
-
Remuneration and social security454/9
-
-
-
€0.2m
€0.2m
€0.2m
€0.3m
€0.2m
▼ 36.0%
Line
2018
2019
2020
2021
2022
2023
2024
2025
Change
Profit (loss) for the period9904
€1.9m
€1.4m
€1.4m
€1.6m
€1.2m
€1.0m
€1.6m
€1.3m
▼ 22.6%
+ Depreciation and write-downs630
€0.3m
€0.3m
€0.3m
€0.3m
€0.2m
€0.2m
€0.2m
€0.2m
▲ 6.0%
Operating cash flow (approximation)
€2.1m
€1.7m
€1.7m
€1.9m
€1.4m
€1.2m
€1.8m
€1.5m
▼ 19.4%
Investment in fixed assets (approximation)
-
-€0.2m
-€0.2m
-€0.2m
-€0.3m
-€0.1m
-€0.2m
-€0.3m
▼ 33.6%
Change in cash
-
€202
€0.03m
€0.2m
-€0.2m
-€0.03m
-€0.009m
€0.01m
-
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Of the 148 active companies whose main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100), figures are known for 109. 24 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts
3 awards · 2024 to 2025
Raamovereenkomst voor aankoop van 18F FDG voor PET Scan
buyer: AZ Sint-Jan Brugge AVMedical equipment and pharmaceuticalsawarded 16-12-2025€1.5m2 tendersTED 17176-2026
CHL: fourniture de [18F]fluorodéoxyglucose.: FDG.
buyer: Centre Hospitalier de Luxembourg (CHL)Medical equipment and pharmaceuticalsawarded 14-10-2024€607,0001 tenderTED 708841-2025
18F-FDG VOOR HET PET/CT CENTRUM
buyer: Vzw AZ Sint-Lucas & VolkskliniekPetroleum products, fuel and electricityawarded 20-08-2024€1.4m2 tendersTED 518279-2024
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.
Directors
Directors
Directors
Who runs the company today and since when, grouped the way the KBO groups its office holders. Many recent board changes are a reason to keep a close eye.
Still in office according to the deeds, but no deed of the last six years confirms the mandate. Mandates like this have often ended since, in a deed we have not read yet.
Who held which function and when, per person: one bar per period, from appointment to resignation or to today. An open left edge means the mandate began before the oldest act we hold.
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it.
The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
The company's story in a few sentences, from the company register, the Belgian Official Gazette and the filed annual accounts. Each number opens the document the sentence rests on.
On 16 December 2002, BETAPLUS PHARMA was incorporated.1Of the 5 current board members, Philippe DEHASPE has served longest, since 2008.2Turnover went from €6.0m in 2018 to €5.4m in 2025 and headcount from 10.5 to 11.3 full-time equivalents.3
Director reappointment, Benoit Woessmer (director)
Auditor emoluments, “€10,660 HTVA, chaque année en tenant compte de l'évolution de l'indice santé” (deed in French)
Auditor additional fees, “frais directs contractés spécifiquement auprès de tiers relatifs aux cotisations variables sur chiffre d'affaires (y compris cotisation par mandat) versés à l'I…” (deed in French)
10-06
NBB filingAnnual accounts filed
financial year 2020 · full format
03-03
Gazette deedReappointments: Stéphan Mairlot (director) and Renaud Dehareng (director)